|
|
||||||||






* Division of Developmental Immunology,
Division of Vaccine Discovery, and
Division of Molecular Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037
| Abstract |
|---|
|
|
|---|
, TNF, IL-2, IL-10, and IL-17). Interestingly, IL-17 and IFN-
production within epitope-specific cells was found to be mutually exclusive. CD4 T cells recognizing a peptide derived from m09 were only detectable at later times of infection and displayed a unique cytokine production profile. In total, this study reveals that the MCMV-specific CD4 T cell response is complex and functionally diverse, highlighting its important role in controlling this persistent pathogen. | Introduction |
|---|
|
|
|---|
Approximately 4–5% of the entire CD4 and CD8 T cell compartment is specific for HCMV in seropositive humans (9) and can increase dramatically in the elderly (10, 11). Specific subpopulations of MCMV-specific CD8 T cells also increase over time (e.g., "memory inflation") (12, 13, 14, 15). The phenotype of inflating CD8 T cells is largely "effector-memory"-like (IL-2–CD62LlowCD127–), whereas noninflationary CD8 T cells resemble "central-memory" cells (IL-2-expressing CD62LhighCD127high cells) (16).
To gain more insight into the CD4 T cell response to MCMV infection, we set out to identify virus peptide-specific CD4 T cell responses restricted by MHC class II (I-Ab). Using a newly developed algorithm, we identified 15 MCMV peptide-specific CD4 T cell responses. Most of these responses displayed "classical" kinetics for the expansion/contraction phase and produced a varied pattern of cytokine expression upon reactivation. In contrast, a CD4 T cell response specific for the m09133–147 peptide was found to be inflationary and displayed a more central-memory phenotype, producing large amounts of IL-2. This study indicates that MCMV-specific CD4 T cell responses are diverse and polyfunctional and provides insight into how these lymphocytes may regulate the pathogenesis of CMV infection.
| Materials and Methods |
|---|
|
|
|---|
C57BL/6 mice were purchased from The Jackson Laboratory. Mice aged 8–12 wk were infected i.p. with 5 x 104 PFU of MCMV (Smith strain; American Type Culture Collection). Virus was prepared from salivary glands of infected BALB/c mice and titered on 3T3 cells as described (17). All studies were conducted at the La Jolla Institute for Allergy and Immunology (La Jolla, CA) in facilities approved by the American Association for the Accreditation of Laboratory Animal Care and according to Institutional Animal Care and Use Committee-approved animal protocols.
Peptide predictions and synthesis
Candidate 15-mer class II epitopes were predicted as described (18), by converting the predictions into a ranking of candidate peptides. From all of the predicted MCMV open reading frames (ORFs) (19), the top 100 predicted I-Ab restricted peptides from the entire MCMV genome were synthesized. In addition, the top 100 peptides from five MCMV proteins that elicit immunodominant CD8 T cell responses (i.e., M45, M57, m139, M38, and IE3) (16) were also synthesized (
80% pure) (Pepscan Systems). Of these 200 peptides, 12 were predicted by both methods and the resulting 188 unique "crude" peptides were tested individually. The 15 MCMV-specific peptides that showed specific CD4 T cell reactivity after this initial analysis were then synthesized as highly purified peptides by A&A Systems, confirmed by mass spectrometry, and used in future experiments.
Intracellular cytokine staining and flow cytometry
Single-cell suspensions of spleens, lymph nodes, and salivary glands from MCMV-infected mice were stimulated in 96-well plates (1.5 x 106/well) with 3 µg/ml peptide for 8 h (the last 6 h in the presence of 1 µg/ml brefeldin A (Golgiplug; BD Pharmingen) at 37°C. Subsequently, cells were stained in PBS containing 1% FCS and 0.05% sodium azide (FACS buffer) with mAbs specific for CD4 (clone RM4-5) and CD8 (clone 53-6.7), fixed and permeabilized according to Cytofix/Cytoperm kit instructions (BD Pharmingen), and intracellular cytokine staining was performed for IFN-
(clone XMG1.2), IL-2 (clone JES6–5H4), IL-10 (clone JES5–16E3), IL-17 (clone TC11–18H10.1), and/or TNF (clone MP6-XT22). All Abs were purchased from either BD Pharmingen or eBioscience. A LSRII flow cytometer with Diva software was used (BD Pharmingen) and data were analyzed with FlowJo software (Tree Star). Two independent experiments were performed for each peptide in multiple mice.
| Results |
|---|
|
|
|---|
To date, no MCMV epitope-specific CD4 T cell responses have been described. To identify class II (I-Ab)-restricted MCMV peptide epitopes, all of the MCMV ORFs were used for algorithm-based predictions, and the 100 most highly ranked 15-mer peptides were synthesized. In addition, the top 100 ranked 15-mer peptides predicted from five MCMV proteins that elicit immunodominant CD8 T cell responses were also synthesized (M45, M57, m139, M38, and IE3) (16). The ability of these peptides to induce MCMV-specific CD4 T cell activation was determined by the restimulation of splenocytes and intracellular cytokine staining for IFN-
8 days after MCMV infection of C57BL/6 mice (Fig. 1A). A total of 14 peptides derived from 10 distinct MCMV proteins activated CD4 T cells above the threshold value of 0.015% (3x over background) and did not activate CD8 T cells (Table I and Fig. 1). The responses specific for peptides m18872–886, M25409–423, m139560–574, m141181–195, and m14224–38 comprised >0.1% of total splenic CD4 T cells. Additional responses ranging from 0.02 to 0.1% were detected for M45102–116, M45192–206, M45239–253, M45796–810, M83229–307, M104261–275, M122/IE3390–404, m139497–511, and m1461–15. The sum of these individual responses represented
1.5% of the total splenic CD4 T cells following MCMV infection. The entire MCMV-specific CD4 T cell population in the spleen was estimated to be
6% of the total population 8 days after MCMV infection based on restimulation with PMA/ionomycin (
9.5% IFN-
+ CD4 T cells in MCMV-infected mice and
3.5% IFN-
+ in naive mice), indicating that
25% of the MCMV-specific CD4 T cell response is likely detected using these 14 epitopes.
|
|
Cellular immune control of MCMV replication during infection is organ specific, with CD4 T cells playing a very important role in both the lungs and salivary gland (2, 3, 4). Consequently, the numbers of MCMV-specific CD4 T cells were examined in the lungs, salivary glands, and their draining lymph nodes 8 days postinfection. A high frequency of these cells were found to be present in the lung at day 8 postinfection (Fig. 1B) and made up a significantly higher percentage of the total CD4 T cells when compared with the spleen. In contrast, only very few MCMV-specific CD4 T cells could be detected in the salivary glands and the draining lymph nodes at this time point (10- to 20-fold lower percentages than in the spleen; data not shown). Thus, MCMV-specific CD4 T cells reside in both lymphoid and nonlymphoid organs and are present in high numbers at times in the lung, where they are critical for viral control.
Cytokine expression profiles of MCMV-specific CD4 T cells
Diverse subsets of CD4 T cells can be identified based on the spectrum of cytokines they produce when encountering Ag (i.e., Th1, Th2, Th17, and regulatory T cells). To identify which subsets develop during acute MCMV infection, we examined the ability of MCMV-specific CD4 T cells to produce TNF, IL-2, IL-10, and IL-17 after peptide stimulation (Fig. 2). During the acute phase of infection, we found that 30–40% of the MCMV-specific, IFN-
expressing CD4 T cells also produced TNF. Upon restimulation, the percentage of peptide-specific CD4 T cells that produced IL-2 varied between
0.1 and 0.2% (tested for m18872–886, M25409–423, m139560–574, m141181–195, and m14224–38); IL-2 was expressed preferentially in cells that did not express IFN-
, but a significant percentage of cells did coexpress these two cytokines (
20–30%). IL-10, a cytokine known to dampen Th1 responses and promote persistent MCMV replication in the salivary gland of B6 mice (20), showed a very similar expression pattern to that of IL-2. In contrast to IL-2 and IL-10, CD4 T cells that expressed IL-17 were never found to coexpress IFN-
and were present at 40–60% as compared with IFN-
-expressing cells. Collectively, these data show that polyfunctional subsets of Ag-specific CD4 T cells develop during MCMV infection.
|
The MCMV-specific, polyclonal memory CD8 T cell pool displays several phenotypes. These range from "classical" responses that expand maximally by
8 days postinfection, contract, and develop into stable long-term memory cells to so-called "inflationary" CD8 T cell memory responses that are virtually undetectable at day 8 but increase dramatically in frequency during chronic/latent infection (15, 21). Consequently, we measured the time course kinetics of the MCMV-specific CD4 T cell response periodically through day 100 postinfection. We found that all 14 responses originally identified at day 8 postinfection peaked at this time and then contracted and established a stable memory cell pool (Fig. 3A).
|
+ population and also produced higher levels of these cytokines (Fig. 3C). Therefore, m09-specific CD4 T cells display a significantly altered time course of induction than that of most MCMV-specific CD4 responses, somewhat resembling inflationary CD8 T cells, but their cytokine expression profiles differ significantly from those of previously characterized MCMV-specific CD8 T cells that increase in number over time. | Discussion |
|---|
|
|
|---|
25% of the IFN-
-producing CD4 T cell population specific for the virus. This result is a marked improvement over our past experiences predicting H-2 I-Ab-restricted, vaccinia virus-derived CD4 T cell epitopes (22). The performance improvements are due to more available public data sets that can be incorporated into next generation algorithms that use a consensus-based approach. Two H-2b-restricted CD8 T cell responses specific for peptides derived from the immediate early (IE) 3 protein increase in number throughout the latent infection of C57BL/6 mice, and these cells display an effector-memory phenotype (IL-2–CD62LlowCD127–) (16). In contrast, the CD4 T cell population specific for the IE3390–404 epitope identified in this study was not found to increase over time. One potential explanation for the inflation of CD8 T cell responses specific for CMV IE proteins is that periodic, stochastic reactivation of a latent virus is a source of chronic Ag(s) for these CD8 T cells (23). For MCMV it has been shown that a CD8 T cell population specific for a H-2d-restricted IE1-derived epitope localizes to the lung and regulates "abortive transcriptional reactivation" (24). Why then do IE3390–404 specific CD4 T cells not inflate if this process is merely driven by chronic Ag? Currently, we have no definitive explanation for this, but the increase in specific CD8 T cell populations during chronic CMV infection cannot likely be exclusively explained by the above model.
Four of the 15 CD4 T cell responses identified in this study are specific for the M45 protein, and M45 is the target of the immunodominant CD8 T cell response during acute MCMV infection in C57BL/6 mice (25). M45 is required for MCMV to inhibit apoptosis and replicate efficiently in endothelial cells (26), cells that express both MHC class I and II. Stromal cells are the primary targets of MCMV infection in the spleen (27) and likely in other organs, suggesting that infected endothelial cells may serve as an important source of viral Ag to promote both CD4 and CD8 T cell responses.
Strikingly, a substantial percentage of the MCMV-specific CD4 T cell population produced IL-17 upon peptide stimulation. To date, very little is known about the role of this cytokine in the context of viral infection. IL-17-producing CD4 T cells are critical for controlling Mycobacterium tuberculosis infection in the lung and do so by regulating the recruitment of IFN-
-producing CD4 T cells (28). As we have observed a significant number of IFN-
-producing, MCMV-specific CD4 T cells in lung, it is tempting to speculate that IL-17 might play a similar role in controlling MCMV infection. In total, this study characterizes specific CD4 T cell responses that arise during MCMV infection and will help to further our understanding of the ways CD4 T cells regulate immunity to infection with this persistent virus.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported in part by a Veni Grant from The Netherlands Organization for Scientific Research (to R.A.), National Institutes of Health (NIH) Grants AI048073 and AI057840, NIH Contract HHSN26620040006C, Pacific Southwest Regional Center of Excellence Grant U54AI065359, and NIH Contract N01-AI-40023 (to A.S. and B.P.), Deutsche Forschungsgemeinschaft (DFG) fellowship (to A.L.), and NIH Grants CA081261 and AI076972 (to S.P.S.). ![]()
2 Address correspondence and reprint requests to Dr. Chris A. Benedict (communicating author for editorial and production offices), Division of Molecular Immunology, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037. E-mail address: benedict{at}liai.org or Dr. Bjoern Peters, Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037. E-mail address: bpeters{at}liai.org ![]()
3 Abbreviations used in this paper: MCMV, mouse CMV; IE, immediate early; ORF, open reading frame. ![]()
Received for publication February 6, 2008. Accepted for publication March 18, 2008.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. H. Munn Th17 cells in ovarian cancer Blood, August 6, 2009; 114(6): 1134 - 1135. [Full Text] [PDF] |
||||
![]() |
M. D. Sharma, D.-Y. Hou, Y. Liu, P. A. Koni, R. Metz, P. Chandler, A. L. Mellor, Y. He, and D. H. Munn Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes Blood, June 11, 2009; 113(24): 6102 - 6111. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |